Modality
Degrader
MOA
PD-1i
Target
SMN2
Pathway
RNA Splicing
AML
Development Pipeline
Preclinical
~Apr 2023
→ ~Jul 2024
Phase 1
Oct 2024
→ Aug 2026
Phase 1Current
NCT06497427
668 pts·AML
2024-10→2026-08·Terminated
668 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-08-124mo awayInterim· AML
Trial Timeline
Q42025Q2Q3Q42026Q2Q3
P1
Termina…
Catalysts
Interim
2026-08-12 · 4mo away
AML
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06497427 | Phase 1 | AML | Terminated | 668 | EFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| NVO-6275 | Novo Nordisk | Phase 1 | SMN2 | |
| GSK-7987 | GSK | Phase 3 | MDM2 | |
| TAK-5300 | Takeda | Phase 1 | SMN2 | |
| GIL-2259 | Gilead Sciences | Approved | SMN2 | |
| REG-647 | Regeneron | Preclinical | SMN2 | |
| Nirabrutinib | BioNTech | Phase 2/3 | CDK2 | |
| Cevinaritide | Genmab | Phase 2/3 | DLL3 | |
| Olpafutibatinib | Immunocore | Approved | SMN2 | |
| ZYM-2450 | Zymeworks | Phase 2 | GLP-1R | |
| Nidarelsin | Uniqure | Phase 2/3 | RET |